大家所关心的药证申请进度
网址: http://ppt.cc/mJh2
In November 2014, the FDA granted MM-398 plus 5-FU and leucovorin a Fast
Track designation as a second-line treatment for patients with metastatic
pancreatic cancer, based on data from the NAPOLI-1 study. As part of this
review program, the company developing MM-298, Merrimack Pharmaceuticals, can
submit information for a New Drug Application for MM-398 to the FDA in
sections. The company plans to complete this submission process within the
first few months of 2015.